about
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatmentFifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancerAnalysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracyOutcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets.Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis.Proposal of supervised data analysis strategy of plasma miRNAs from hybridisation array data with an application to assess hemolysis-related deregulation.Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates-Preliminary data: Medical ozone gas insufflation in treating ONJ lesionsTetracaine oral gel in patients treated with radiotherapy for head-and-neck cancer: final results of a phase II study.Thyroid disorders in patients treated with radiotherapy for head-and-neck cancer: a retrospective analysis of seventy-three patients.Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers.Phase II study on lapatinib in advanced EGFR-positive chordoma.Estimation of predictive accuracy in survival analysis using R and S-PLUS.Peniscopically controlled CO2 laser excision for conservative treatment of in situ and T1 penile carcinoma: report on 224 patients.Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group.Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer.Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer.Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study.Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes.Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups.Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution.Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study.Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution.Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial.Survival prediction for terminally ill cancer patients: revision of the palliative prognostic score with incorporation of deliriumCombination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical OncologyEndocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.Resection of hepatocellular cancer ≤2 cm: results from two Western centers.Screening of related donors and peripheral blood stem cell collection practices at different Italian apheresis centres.Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II studySYT-SSX fusion genes and prognosis in synovial sarcoma.Results of a breast-cancer-surgery trial compared with observational data from routine practice.GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational studyLymph node metastases in malignant tumors of the paranasal sinuses: prognostic value and treatment.Polymorphisms of Metabolizing Enzymes and Susceptibility to Ethmoid Intestinal-type Adenocarcinoma in Professionally Exposed PatientsPulmonary nodules: volume repeatability at multidetector CT lung cancer screening.Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
P50
Q24656967-94979EEF-D7B6-408A-BC23-C32FF8903464Q28238331-931FD632-7121-426D-8F28-644978AA7E5BQ30563774-E12C1882-D203-4D50-881E-203464D79AD4Q30607290-02EACD25-E2E5-4D0F-A95E-FCA32CDE1DB2Q30650708-7FA4A16E-E4FE-4F83-B203-4AD0E08C0EDAQ31025891-CEB2C900-D48D-418A-B1D7-CEA5E1D7DD5EQ31048683-24A09327-4CA7-4A8E-B6A5-A40A7E4D08FDQ33225850-DE7C6DE4-09B5-4A83-97FF-0161B2D2FB39Q33262700-A2292438-C6E5-40AE-8093-A10963A8AB4EQ33273555-3F31975B-18CA-4635-ACE3-2FF95570E660Q33274760-DC11CE2D-349C-41AB-8698-03ADCF2F8D95Q33289347-E05508FA-82D2-4316-B6D6-9FB35714C946Q33317905-6C080053-9AFD-44C8-8276-1367EDC2DBC4Q33341367-1CBE5C9E-980B-430B-9F94-0F9E9A0219DEQ33346351-A64EAF58-3677-45BE-A933-80BC7750A14FQ33358688-F778172D-39E4-43F2-89BB-2B794DC74ED3Q33373314-01FF9FAE-1E51-43E1-A175-C02B5F0DD8DCQ33376670-319B7156-5E58-47EA-A524-88B3334C8739Q33409143-F77BAD28-CCFC-4C12-B9BB-CB9CDB0DDE51Q33412487-83465F3A-0FB3-4B6F-9081-3400EFFBBFDEQ33413496-62FF1B1F-4A1B-44BE-A27F-7803997DCDB5Q34141311-2735AA3A-4E3E-434C-93F3-01398FFDF64EQ34154064-8917EF7B-492F-4F65-8758-60EA55D05BC7Q34532365-938B84D3-6098-46F1-AABE-7E0CD3F3B3D4Q34551964-1A0AE177-87EE-4E29-BECA-20671D8A9900Q34579626-C30B4508-2FAC-48D4-9013-B5AFAABBAD4EQ34658767-A6AB1DB0-D15E-4D35-AF8B-5BB8D99B7573Q35642409-45E9D9DC-7231-4589-9006-ED4335FE1B7FQ36080911-27C6B298-F119-4835-B4A7-E0F70D6E7508Q36081653-8723C24B-8585-46B4-8BAC-E90580436586Q36233505-70B33F60-B1F2-4ADB-9B82-9908529E7308Q36393487-42E173C3-0045-4874-91D1-33AF74CB69FAQ36609827-B56E8F85-C676-4596-A967-9B8E0172BB4DQ36623165-35197C23-91C1-488D-8E50-A18D014E481BQ36796452-B9AF5CAF-A718-4165-93B0-69B24ECB6A05Q36879706-50CB8439-547F-4A7D-AFBE-DC50E26FA928Q37087890-4638FC9D-AC97-44A7-97D2-01C22AEF72A0Q37162095-7BA4BB71-C9B3-44DF-8C8B-2789670C9997Q37452513-D5150363-D5E5-4C54-92F8-ED5EED92A2B0Q38028124-A89B289A-D1BB-4F31-8FDB-041C8DC66391
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Luigi Mariani
@ast
Luigi Mariani
@en
Luigi Mariani
@es
Luigi Mariani
@it
Luigi Mariani
@sl
type
label
Luigi Mariani
@ast
Luigi Mariani
@en
Luigi Mariani
@es
Luigi Mariani
@it
Luigi Mariani
@sl
prefLabel
Luigi Mariani
@ast
Luigi Mariani
@en
Luigi Mariani
@es
Luigi Mariani
@it
Luigi Mariani
@sl
P1053
C-2580-2017
P106
P1153
35240723100
P21
P31
P3829
P496
0000-0001-6208-4084